The passing of former Federal Reserve Chairman Alan Greenspan has pushed monetary policy back into the spotlight, with investors reassessing how interest rates, liquidity and risk appetite shape the outlook for large financial institutions. For stocks in our Financial Sector Stocks screener, this renewed focus on Fed decisions and “irrational exuberance” can influence how investors view balance sheet strength, earnings quality and valuation. This article walks through 3 stocks from that screener that appear positively exposed to the current debate around central bank policy, helping you decide whether they merit a closer look or a place on your watchlist.

Lemonade (LMND)

Overview: Lemonade is a New York based, app driven insurer that sells renters, homeowners, auto, pet, life and landlord policies. It uses automation and artificial intelligence to handle quotes, underwriting and claims in the United States, parts of Europe and the United Kingdom.

Operations: Lemonade generates all of its US$844.7 million in revenue from property and casualty insurance in the United States.

Market Cap: US$4.42b

For investors reassessing financial stocks through the lens of Alan Greenspan’s “irrational exuberance” warning, Lemonade offers a useful test case that combines a technology heavy insurance model with clear interest rate and regulatory exposure. The company is still loss making with a negative return on equity and relies on higher risk external funding. At the same time, revenue growth, narrowing losses and analyst expectations for profitability within 3 years illustrate why sentiment has improved. Rapid product and geographic expansion, including new renters and autonomous car insurance launches across multiple US states in 2026, supports scale but also raises questions about claim volatility and customer acquisition costs. How this balance between growth, AI driven efficiency and underwriting risk develops is central to how some investors may view Lemonade in the current Fed focused debate.

Lemonade’s revenue growth story and push toward profitability often grab attention, but the real question is whether that momentum can offset its loss making profile and funding risks, which the analyst forecasts for Lemonade starts to unpack before raising a crucial twist.

Flagstar Bank National Association (FLG)

Overview: Flagstar Bank National Association is a US regional bank that offers deposits, a wide range of commercial and real estate loans, consumer lending and wealth products to individuals, small and mid size businesses and professional associations through both branches and digital channels.

Operations: Flagstar Bank generates US$2.0b in revenue from its banking operations in the United States.

Market Cap: US$6.26b

Flagstar Bank sits squarely in the crosshairs of the renewed Greenspan era debate, where interest rate cycles, credit quality and liquidity decisions can quickly reshape investor expectations for regional lenders. The story here is a mix of opportunity and tension, with analysts modeling revenue and earnings trends, a move from losses toward profitability and a P/B ratio below many US peers, while credit risks linger through higher bad loan levels and relatively low loss allowances. At the same time, technology upgrades such as the Flagstar S2 platform and StarIQ AI system, together with a push into higher spread commercial lending and private banking, are quietly changing how this bank earns and funds itself. However, the implications for returns and risk are not yet fully reflected in headline numbers.

Flagstar Bank’s earnings shift and P/B discount both stand out, but the real tension is what might be hiding in its credit book, which the 1 key reward and 2 important warning signs could reveal in an unexpected way

Oscar Health (OSCR)

Overview: Oscar Health is a New York based healthcare technology company that sells health insurance plans to individuals, families, employees and small businesses, while also licensing its +Oscar and Campaign Builder platforms to other healthcare players and offering digital tools for brokers and consumers to shop for and enroll in coverage.

Operations: Oscar Health generates about US$13.3b in revenue from life and health insurance in the United States.

Market Cap: US$8.60b

Oscar Health sits at the intersection of insurance, technology and regulation. This is exactly where the Greenspan era conversation about interest rates, risk taking and “irrational exuberance” is now being re-examined. The company has moved toward an earnings inflection, with recent quarters showing strong revenue, positive net income and management talking about hundreds of millions of operating earnings if underwriting discipline and cost cuts hold. At the same time, heavy reliance on the ACA exchange market, higher claims costs and possible policy changes around subsidies leave margins exposed if pricing or membership shifts. Add in fast revenue growth, a P/S ratio below many US insurance peers and a debate over whether analysts are underestimating or overestimating its potential, and Oscar Health becomes a stock where the full story is still unfolding for investors willing to dig deeper into the details.

Oscar Health’s earnings turnaround talk and ACA exposure raise a bigger question, and the analyst forecasts for Oscar Health lays out where expectations are stretching and where a single assumption could change the whole story

The three financial stocks covered here are just a starting point, with the full Financial Sector Stocks screener surfacing 32 more large cap companies whose balance sheets, risk scores and business models present equally compelling narratives around monetary policy and financial sector themes. Use Simply Wall St to identify and analyze the specific catalysts that matter to you, filtering for earnings quality, risk factors and valuation signals so you can focus on the financial sector ideas that best match your highest conviction strategies.

Take Control of Your Investment Journey

If Oscar Health or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Stocks?

Fresh opportunities do not wait around. While attention clusters on the obvious trades, quieter stocks can build momentum under the radar for now. Before the crowd catches on, consider exploring new ideas.

• Spot fast moving opportunities in early stage companies before attention spikes by scanning the 24 elite penny stocks with strong financials curated for stronger balance sheets and healthier fundamentals.
• Explore the next wave of automation momentum by tracking the 31 robotics and automation stocks where earnings power, cash flow quality and capital discipline are front and center.
• Monitor the digital infrastructure shift by zeroing in on the 49 AI infrastructure stocks built to surface companies supporting the heavy lifting behind AI growth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.